(Q36794538)

16 August 2017

1 reference

title

Therapeutic targets in chronic myeloid leukaemia (English)

1 reference

16 August 2017

1 reference

Tessa L Holyoake

2

0 references

author name string

Nicholas B Heaney

series ordinal

1

1 reference

16 August 2017

publication date

1 June 2007

1 reference

16 August 2017

published in

Hematological Oncology

1 reference

16 August 2017

volume

25

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

66-75

1 reference

16 August 2017

cites work

Chronic myeloid leukemia

1 reference

7 January 2021

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

7 January 2021

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

7 January 2021

Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission

1 reference

7 January 2021

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

1 reference

7 January 2021

Discontinuation of imatinib therapy after achieving a molecular response

1 reference

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

7 January 2021

Tumour stem cells and drug resistance

1 reference

7 January 2021

A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia.

1 reference

7 January 2021

Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.

1 reference

7 January 2021

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

7 January 2021

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

1 reference

7 January 2021

Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli

1 reference

7 January 2021

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

1 reference

7 January 2021

Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.

1 reference

7 January 2021

Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia

1 reference

7 January 2021

Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate

1 reference

7 January 2021

GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia

1 reference

7 January 2021

Addition of sargramostim (GM-CSF) to imatinib results in major cytogenetic response in a patient with chronic myeloid leukemia

1 reference

7 January 2021

Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia

1 reference

7 January 2021

Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia

1 reference

7 January 2021

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

7 January 2021

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

7 January 2021

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

7 January 2021

Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure

1 reference

7 January 2021

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

1 reference

7 January 2021

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias

1 reference

7 January 2021

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

1 reference

7 January 2021

The Role of ABC Transporters in Clinical Practice

1 reference

7 January 2021

Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells

1 reference

7 January 2021

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

1 reference

7 January 2021

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

1 reference

7 January 2021

Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment

1 reference

7 January 2021

Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG.

1 reference

7 January 2021

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

1 reference

7 January 2021

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate

1 reference

7 January 2021

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro

1 reference

7 January 2021

Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression

1 reference

7 January 2021

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

7 January 2021

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

1 reference

7 January 2021

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

1 reference

7 January 2021

Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.

1 reference

7 January 2021

BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B.

1 reference

7 January 2021

Heat shock protein 90 as a molecular target for cancer therapeutics

1 reference

7 January 2021

The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy

1 reference

7 January 2021

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

1 reference

7 January 2021

Punish the parent not the progeny.

1 reference

7 January 2021

The proteasome: a novel therapeutic target in haematopoietic malignancy

1 reference

7 January 2021

Abnormally high expression of proteasomes in human leukemic cells

1 reference

7 January 2021

Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies

1 reference

7 January 2021

A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation

1 reference

7 January 2021

p27 deregulation in breast cancer: prognostic significance and implications for therapy

1 reference

7 January 2021

BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells

1 reference

7 January 2021

Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function.

1 reference

7 January 2021

Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors

1 reference

7 January 2021

Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.

1 reference

7 January 2021

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

1 reference

7 January 2021

Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I.

1 reference

7 January 2021

The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI.

1 reference

7 January 2021

Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells

1 reference

7 January 2021

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

1 reference

7 January 2021

The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance

1 reference

7 January 2021

Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl

1 reference

7 January 2021

The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism

1 reference

7 January 2021

Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate

1 reference

7 January 2021

Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro

1 reference

7 January 2021

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

1 reference

7 January 2021

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach

1 reference

7 January 2021

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

1 reference

7 January 2021

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

1 reference

7 January 2021

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

1 reference

7 January 2021

Identifiers

DOI

10.1002/HON.813

1 reference

16 August 2017

1 reference